Laura Gramantieri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4879285/publications.pdf

Version: 2024-02-01

104	8,416	66343	45317
papers	citations	42 h-index	90 g-index

106	106	106	10824
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer Research, 2007, 67, 6092-6099.	0.9	782
2	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	16.8	681
3	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27, 5651-5661.	5.9	619
4	Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001, 48, 251-259.	12.1	567
5	MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2010, 70, 5184-5193.	0.9	389
6	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2009, 69, 5761-5767.	0.9	380
7	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. Clinical Cancer Research, 2009, 15, 5073-5081.	7.0	298
8	Oncogenic Role of miR-483-3p at the IGF2/483 Locus. Cancer Research, 2010, 70, 3140-3149.	0.9	272
9	What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. Journal of Hepatology, 1997, 27, 979-985.	3.7	256
10	MicroRNA involvement in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2008, 12, 2189-2204.	3.6	248
11	In hepatocellular carcinoma miRâ€519d is upâ€regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. Journal of Pathology, 2012, 227, 275-285.	4.5	180
12	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology, 2012, 56, 1025-1033.	7.3	150
13	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology, 1999, 30, 58-64.	7.3	141
14	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death and Differentiation, 2015, 22, 46-57.	11.2	140
15	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3â€“Mediated Apoptosis. Clinical Cancer Research, 2017, 23, 3953-3965.	7.0	137
16	Significance of serum and hepatic micro<scp>RNA</scp>â€122 levels in patients with nonâ€alcoholic fatty liver disease. Liver International, 2014, 34, e302-7.	3.9	124
17	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS ONE, 2015, 10, e0141448.	2.5	113
18	Oxidative Stress EPR Measurement in Human Liver by Radical-probe Technique. Correlation with Etiology, Histology and Cell Proliferation. Free Radical Research, 2002, 36, 939-948.	3.3	97

#	Article	IF	Citations
19	Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer. Cancer Research, 2004, 64, 8156-8159.	0.9	96
20	Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver International, 2007, 27, 997-1007.	3.9	96
21	Hepatocellular carcinoma: Epidemiology and clinical aspects. Molecular Aspects of Medicine, 2008, 29, 130-143.	6.4	92
22	microRNA Involvement in Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 500-521.	1.7	88
23	Selective ablation of Notch3 in HCC enhances doxorubicinâ€™s death promoting effect by a p53 dependent mechanism. Journal of Hepatology, 2009, 50, 969-979.	3.7	87
24	Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. Oncotarget, 2016, 7, 32375-32393.	1.8	83
25	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5445-5449.	7.1	81
26	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids, 2018, 11, 485-493.	5.1	81
27	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget, 2018, 9, 15350-15364.	1.8	79
28	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death and Disease, 2018, 9, 4.	6.3	68
29	Value of splanchnic Doppler ultrasound in the diagnosis of portal hypertension. Ultrasound in Medicine and Biology, 2001, 27, 893-899.	1.5	66
30	The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1Î± Activity by Changing miR Expression Patterns in Human Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 239-248.	4.1	63
31	Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats. Hepatology, 2015, 61, 249-259.	7.3	63
32	CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. American Journal of Pathology, 2012, 181, 413-422.	3.8	58
33	Role of microRNAs in hepatocellular carcinoma: a clinical perspective. OncoTargets and Therapy, 2013, 6, 1167.	2.0	56
34	Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene, 2019, 38, 7035-7045.	5.9	55
35	Intra- and extrahepatic arterial resistances in chronic hepatitis and liver cirrhosis. Ultrasound in Medicine and Biology, 1997, 23, 675-682.	1.5	54
36	Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus. PLoS ONE, 2013, 8, e73964.	2.5	53

#	Article	IF	Citations
37	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene, 2002, 21, 2564-2572.	5.9	52
38	Serum Xanthine Oxidase in Human Liver Disease. American Journal of Gastroenterology, 2001, 96, 1194-1199.	0.4	49
39	Mutated Î²-catenin evades a microRNA-dependent regulatory loop. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4840-4845.	7.1	48
40	MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.	0.9	47
41	LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget, 2018, 9, 35085-35099.	1.8	46
42	Assessment of Vascular Patterns of Small Liver Mass Lesions: Value and Limitation of The Different Doppler Ultrasound Modalities. American Journal of Gastroenterology, 2000, 95, 3537-3546.	0.4	45
43	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	1.8	45
44	p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. Molecular Cancer Research, 2014, 12, 203-216.	3.4	43
45	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Frontiers in Genetics, 2013, 4, 64.	2.3	42
46	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3Î² phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget, 2013, 4, 1618-1631.	1.8	42
47	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. Journal of Hepatology, 2003, 39, 997-1003.	3.7	40
48	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget, 2014, 5, 10607-10620.	1.8	39
49	Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. Journal of Hepatology, 2020, 72, 1159-1169.	3.7	38
50	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology, 2000, 31, 349-357.	7.3	37
51	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Journal of Clinical Medicine, 2019, 8, 171.	2.4	37
52	Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. International Journal of Molecular Sciences, 2017, 18, 56.	4.1	35
53	The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. Journal of Hepatology, 2016, 64, 891-898.	3.7	34
54	Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis and Therapy, 2003, 7, 201-207.	1.1	33

#	Article	IF	Citations
55	Superior mesenteric artery impedance in chronic liver diseases: relationship with disease severity and portal circulation. American Journal of Gastroenterology, 1998, 93, 1925-1930.	0.4	32
56	Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. European Journal of Gastroenterology and Hepatology, 1997, 9, 799-804.	1.6	31
57	GADD45-Î± expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. Human Pathology, 2005, 36, 1154-1162.	2.0	31
58	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. European Journal of Medicinal Chemistry, 2012, 48, 391-401.	5.5	29
59	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 741-757.	3.7	29
60	Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Research, 2006, 26, 2123-7.	1.1	29
61	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2015, 2, 29.	3.7	26
62	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2016, 17, 2029.	4.1	26
63	Imbalance of IL-1Î² and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Clinical and Experimental Immunology, 1999, 115, 515-520.	2.6	25
64	From liver cirrhosis to HCC. Internal and Emergency Medicine, 2011, 6, 93-98.	2.0	25
65	MicroRNAs in Animal Models of HCC. Cancers, 2019, 11, 1906.	3.7	25
66	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. Oncotarget, 2016, 7, 39609-39626.	1.8	25
67	Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. Journal of Medical Virology, 2000, 62, 25-28.	5.0	24
68	MicroRNA response to environmental mutagens in liver. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 67-76.	1.0	24
69	Role of SIRT-3, p-mTOR and HIF-1Î± in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. International Journal of Molecular Sciences, 2019, 20, 1503.	4.1	24
70	Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). Clinica Chimica Acta, 1999, 281, 147-158.	1.1	22
71	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. Acta Histochemica, 2018, 120, 95-102.	1.8	22
72	Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. Laboratory Investigation, 2008, 88, 995-1007.	3.7	21

#	Article	IF	Citations
73	Diagnostic and prognostic value of dna ploidy and cell nuclearity in ultrasound-guided liver biopsies. Cancer, 1994, 74, 1713-1719.	4.1	20
74	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1319-1326.	2.3	20
75	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. Journal of Hepatology, 1996, 24, 60-65.	3.7	19
76	Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis and Therapy, 2003, 7, 201-207.	1.1	18
77	Circadian occurrence of variceal bleeding in patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 1115-1120.	2.8	17
78	Liver metastases from rectal carcinoma: Disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. Journal of Clinical Ultrasound, 2003, 31, 387-391.	0.8	15
79	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Molecular Therapy - Nucleic Acids, 2019, 14, 239-250.	5.1	14
80	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. Digestive Diseases and Sciences, 2017, 62, 2397-2407.	2.3	13
81	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. Cancers, 2020, 12, 2674.	3.7	13
82	Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	7.0	13
83	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. Cells, 2021, 10, 521.	4.1	13
84	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	3.6	12
85	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 369-385.	3.7	12
86	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. Scientific Reports, 2017, 7, 44685.	3.3	11
87	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
88	Animal Models of Hepatocellular Carcinoma Prevention. Cancers, 2019, 11, 1792.	3.7	10
89	Possible mechanisms for changes of intrasplenic arterial impedance indices in portal hypertension. Hepatology, 1997, 26, 513-514.	7.3	9
90	Alteration of DNA ploidy and cell nuclearity in human hepatocellular carcinoma associated with HBV infection. Journal of Hepatology, 1996, 25, 848-853.	3.7	8

#	Article	IF	Citations
91	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. Digestive Diseases and Sciences, 1996, 41, 800-808.	2.3	8
92	Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. Alimentary Pharmacology and Therapeutics, 1998, 12, 475-481.	3.7	8
93	Brivanib in combination with Notch3 silencing shows potent activity in tumour models. British Journal of Cancer, 2019, 120, 601-611.	6.4	7
94	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. Cancers, 2021, 13, 4550.	3.7	6
95	Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. Oncotarget, 2018, 9, 17895-17905.	1.8	6
96	Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. Nutrients, 2022, 14, 1652.	4.1	6
97	Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate. Digestive Diseases and Sciences, 2000, 45, 306-311.	2.3	5
98	A case of extracranial vertebral artery dissection with spontaneous recovery. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1997, 6, 197-201.	1.3	2
99	Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. Digestive and Liver Disease, 2004, 36, 594-602.	0.9	2
100	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. Biomolecules, 2022, 12, 930.	4.0	2
101	Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. OncoTargets and Therapy, 2021, Volume 14, 4305-4308.	2.0	1
102	Correction: Online Publication Dates for Cancer Research April 15, 2010 Articles. Cancer Research, 2010, 70, 4785-4786.	0.9	0
103	Emerging role of microRNAs in the treatment of hepatocellular carcinoma. Gastrointestinal Cancer: Targets and Therapy, 2015, , 89.	5.5	0
104	Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma. , 2022, , 301-315.		0